SELLAS Says FDA Grants Rare Pediatric Disease Designation For SLS009 To Treat Pediatric ALL
(RTTNews) - Biopharmaceutical company SELLAS Life Sciences Group, Inc. (SLS) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia (ALL).
In clinical trials, SLS009 has demonstrated a very favorable safety profile with complete absence, to date, of any non-hematologic clinical higher-grade toxicities.
If, in the future, a New Drug Application (NDA) for SLS009 for the treatment of pediatric AML is approved by the FDA, SELLAS might be eligible to receive a Priority Review Voucher (PRV) that could be redeemed to receive a priority review for any subsequent marketing application.
PRVs may be used by the sponsor or sold to another sponsor for their use and have recently sold for approximately $100 million.
SELLAS Life Sciences Reports Positive Topline Data In Lymphoma Cohort From SLS009 Phase 1 Trial
Australian Dollar Advances Against Some Majors
European Shares Seen Mixed As Focus Shifts To US-Russia Talks
European Economic News Preview: UK GDP & Foreign Trade Data Due
Yen Rises Against Majors
Sensex, Nifty Marginally Higher Ahead Of US-Russia Talks
Australian Market Extends Early Gains In Mid-market
